Tatsuya Yamasoba

Dr. Tatsuya Yamasoba

University of Tokyo Hospital, Tokyo, Japan
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Hearing Research
Verified
Journal Article
Closed access
Tatsuya YamasobaTatsuya Yamasoba
Tatsuya Yamasoba
FLFrank R. Lin
Frank R. Lin
SSShinichi Someya
Shinichi Someya
AKAkinori Kashio
Akinori Kashio
TSTakashi Sakamoto
Takashi Sakamoto
Kenji KondoKenji Kondo
Kenji Kondo

1 January 2014 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
CFChisato Fujimoto
Chisato Fujimoto
Tatsuya YamasobaTatsuya Yamasoba
Tatsuya Yamasoba
Age-related hearing loss (ARHL), the progressive loss of hearing associated with aging, is the most common sensory disorder in the elderly population. The pathology of ARHL includes the hair cells of the organ of Corti, stria vascularis, and afferent spiral ganglion neurons as well as the central auditory pathways. Many studies have suggested that the accumulation of mitochondrial DNA damage, the production of reactive oxygen species, and decreased antioxidant function are associated with subsequent cochlear senescence in response to aging stress. Mitochondria play a crucial role in the induction of intrinsic apoptosis in cochlear cells. ARHL can be prevented in laboratory animals by certain interventions, such as caloric restriction and supplementation with antioxidants. In this review, we will focus on previous research concerning the role of the oxidative stress and mitochondrial dysfunction in the pathology of ARHL in both animal models and humans and introduce concepts that have recently emerged regarding the mechanisms of the development of ARHL.

22 March 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
TKTeru Kamogashira
Teru Kamogashira
CFChisato Fujimoto
Chisato Fujimoto
Tatsuya YamasobaTatsuya Yamasoba
Tatsuya Yamasoba
Reactive oxygen species (ROS) production is involved in several apoptotic and necrotic cell death pathways in auditory tissues. These pathways are the major causes of most types of sensorineural hearing loss, including age-related hearing loss, hereditary hearing loss, ototoxic drug-induced hearing loss, and noise-induced hearing loss. ROS production can be triggered by dysfunctional mitochondrial oxidative phosphorylation and increases or decreases in ROS-related enzymes. Although apoptotic cell death pathways are mostly activated by ROS production, there are other pathways involved in hearing loss that do not depend on ROS production. Further studies of other pathways, such as endoplasmic reticulum stress and necrotic cell death, are required.

5 January 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
HKHajime Koyama
Hajime Koyama
TKTeru Kamogashira
Teru Kamogashira
Tatsuya YamasobaTatsuya Yamasoba
Tatsuya Yamasoba
Heavy metals are often found in soil and can contaminate drinking water, posing a serious threat to human health. Molecular pathways and curation therapies for mitigating heavy metal toxicity have been studied for a long time. Recent studies on oxidative stress and aging have shown that the molecular foundation of cellular damage caused by heavy metals, namely, apoptosis, endoplasmic reticulum stress, and mitochondrial stress, share the same pathways as those involved in cellular senescence and aging. In recent aging studies, many types of heavy metal exposures have been used in both cellular and animal aging models. Chelation therapy is a traditional treatment for heavy metal toxicity. However, recently, various antioxidants have been found to be effective in treating heavy metal-induced damage, shifting the research focus to investigating the interplay between antioxidants and heavy metals. In this review, we introduce the molecular basis of heavy metal-induced cellular damage and its relationship with aging, summarize its clinical implications, and discuss antioxidants and other agents with protective effects against heavy metal damage.

1 April 2007 in Hearing Research
Verified
Journal Article
Closed access
Tatsuya YamasobaTatsuya Yamasoba
Tatsuya Yamasoba
SSShinichi Someya
Shinichi Someya
CYChikako Yamada
Chikako Yamada
RWRichard Weindruch
Richard Weindruch
TPTomas A. Prolla
Tomas A. Prolla
MTMasaru Tanokura
Masaru Tanokura

24 April 2019 in Antioxidants
Verified
Journal Article
Open access
PDF file
CFChisato Fujimoto
Chisato Fujimoto
Tatsuya YamasobaTatsuya Yamasoba
Tatsuya Yamasoba
Mitochondrial dysfunction is associated with the etiologies of sensorineural hearing loss, such as age-related hearing loss, noise- and ototoxic drug-induced hearing loss, as well as hearing loss due to mitochondrial gene mutation. Mitochondria are the main sources of reactive oxygen species (ROS) and ROS-induced oxidative stress is involved in cochlear damage. Moreover, the release of ROS causes further damage to mitochondrial components. Antioxidants are thought to counteract the deleterious effects of ROS and thus, may be effective for the treatment of oxidative stress-related diseases. The administration of mitochondria-targeted antioxidants is one of the drug delivery systems targeted to mitochondria. Mitochondria-targeted antioxidants are expected to help in the prevention and/or treatment of diseases associated with mitochondrial dysfunction. Of the various mitochondria-targeted antioxidants, the protective effects of MitoQ and SkQR1 against ototoxicity have been previously evaluated in animal models and/or mouse auditory cell lines. MitoQ protects against both gentamicin- and cisplatin-induced ototoxicity. SkQR1 also provides auditory protective effects against gentamicin-induced ototoxicity. On the other hand, decreasing effect of MitoQ on gentamicin-induced cell apoptosis in auditory cell lines has been controversial. No clinical studies have been reported for otoprotection using mitochondrial-targeted antioxidants. High-quality clinical trials are required to reveal the therapeutic effect of mitochondria-targeted antioxidants in terms of otoprotection in patients.